Treatment of rheumatoid arthritis during pregnancy: present and future

References

• Neovius M, Simard JF, Askling J; ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis. 2011;70(4):624–629.
   PubMed Web of Science ®Google Scholar
• Widdifield J, Paterson JM, Bernatsky S, et al. The epidemiology of rheumatoid arthritis in Ontario, Canada. Arthritis Rheum. 2014;66(4):786–793.
   Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.
   PubMed Web of Science ®Google Scholar
• Brouwer J, Hazes JM, Laven JS, et al. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis. 2015;74(10):1836–1841.
   PubMed Web of Science ®Google Scholar
• Ostensen M, Villiger PM, Forger F. Interaction of pregnancy and autoimmune rheumatic disease. Autoimmun Rev. 2012;11(6–7):A437–A446.
   Google Scholar
• Hench PS. Potential reversibility of rheumatoid arthritis. Ann Rheum Dis. 1949;8(2):90–96.
   PubMed Web of Science ®Google Scholar
• Ostensen M, Husby G. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 1983;26(9):1155–1159.
   PubMed Web of Science ®Google Scholar
• Nelson JL, Hughes KA, Smith AG, et al. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med. 1993;329(7):466–471.
   PubMed Web of Science ®Google Scholar
• Barrett JH, Brennan P, Fiddler M, et al. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum. 1999;42(6):1219–1227.
   PubMed Web of Science ®Google Scholar
• de Man YA, Dolhain RJ, van de Geijn FE, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum. 2008;59(9):1241–1248.
   PubMed Web of Science ®Google Scholar
• de Man YA, Bakker-Jonges LE, Goorbergh CM, et al. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy. Ann Rheum Dis. 2010;69(2):420–423.
   PubMed Web of Science ®Google Scholar
• Forger F, Vallbracht I, Helmke K, et al. Pregnancy mediated improvement of rheumatoid arthritis. Swiss Med Wkly. 2012;142:w13644.
   PubMed Web of Science ®Google Scholar
• Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat Reviews Rheumatol. 2009;5(7):382–390.
   PubMed Web of Science ®Google Scholar
• Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76(3):907–912.
   PubMed Web of Science ®Google Scholar
• Dalrymple JM, Stamp LK, O’Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58(11):3299–3308.
   PubMed Web of Science ®Google Scholar
• Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94(4):187–207.
   PubMed Web of Science ®Google Scholar
• Schleuning M, Clemm C. Chromosomal aberrations in a newborn whose mother received cytotoxic treatment during pregnancy. N Engl J Med. 1987;317(26):1666–1667.
   PubMed Web of Science ®Google Scholar
• Reich EW, Cox RP, Becker MH, et al. Recognition in adult patients of malformations induced by folic-acid antagonists. Birth Defects Orig Artic Ser. 1978;14(6B):139–160.
   PubMedGoogle Scholar
• Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheum. 2014;66(5):1101–1110.
   PubMed Web of Science ®Google Scholar
• Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810.
   Google Scholar
• Fox RI, Herrmann ML, Frangou CG, et al. How does leflunomide modulate the immune response in rheumatoid arthritis? BioDrugs. 1999;12(4):301–315.
   PubMed Web of Science ®Google Scholar
• Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology. 2001;63(2):106–112.
   PubMedGoogle Scholar
• Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62(5):1494–1503.
   PubMed Web of Science ®Google Scholar
• Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum. 2012;64(7):2085–2094.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox Pharmacovigilance Center. Reprod Toxicology. 2016;60:29–32.
   PubMed Web of Science ®Google Scholar
• Nishino E, Matsuzaki N, Masuhiro K, et al. Trophoblast-derived interleukin-6 (IL-6) regulates human chorionic gonadotropin release through IL-6 receptor on human trophoblasts. J Clin Endocrinol Metab. 1990;71(2):436–441.
   PubMed Web of Science ®Google Scholar
• Ostensen M, Forger F. How safe are anti-rheumatic drugs during pregnancy? Current Opinion in Pharmacology. 2013;13(3):470–475.
   PubMed Web of Science ®Google Scholar
• Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–1506.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunology. 2010;184(4):1968–1976.
   PubMed Web of Science ®Google Scholar
• Kumar M, Ray L, Vemuri S, et al. Pregnancy outcomes following exposure to abatacept during pregnancy. Semin Arthritis Rheum. 2015;45(3):351–356.
   PubMed Web of Science ®Google Scholar
• Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol. 1977;127(3):264–267.
   PubMed Web of Science ®Google Scholar
• Benediktsson R, Calder AA, Edwards CR, et al. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol. 1997;46(2):161–166.
   PubMed Web of Science ®Google Scholar
• Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209.
   PubMed Web of Science ®Google Scholar
• Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–392.
   PubMedGoogle Scholar
• Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicology. 2004;18(1):93–101.
   PubMed Web of Science ®Google Scholar
• Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ: Can Med Assoc J = journal de l’Association medicale canadienne. 2011;183(7):796–804.
   PubMed Web of Science ®Google Scholar
• Bay Bjorn AM, Ehrenstein V, Hundborg HH, et al. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther. 2014;21(2):73–80.
   PubMed Web of Science ®Google Scholar
• Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992;166(5):1318–1323.
   PubMed Web of Science ®Google Scholar
• de Man YA, Hazes JM, van der Heide H, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. 2009;60(11):3196–3206.
   PubMed Web of Science ®Google Scholar
• Micu MC, Micu R, Ostensen M. Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies. Arthritis Care Res. 2011;63(9):1334–1338.
   Web of Science ®Google Scholar
• Antonucci R, Zaffanello M, Puxeddu E, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012;13(4):474–490.
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2015;2:CD003481.
   PubMed Web of Science ®Google Scholar
• Scherneck S, Schopa FL, Entezami M, et al. Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure. Reprod Toxicology. 2015;58:61–64.
   PubMed Web of Science ®Google Scholar
• O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–318.
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicology. 2008;25(2):271–275.
   PubMed Web of Science ®Google Scholar
• Levi S, Liberman M, Levi AJ, et al. Reversible congenital neutropenia associated with maternal sulphasalazine therapy. Eur J Pediatr. 1988;148(2):174–175.
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343(22):1608–1614.
   PubMed Web of Science ®Google Scholar
• Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016 Jan 10. pii: kev404. [Epub ahead of print]
   Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum. 2002;46(4):1123–1124.
   PubMed Web of Science ®Google Scholar
• Ullberg S, Lindquist NG, Sjostrand SE. Accumulation of chorio-retinotoxic drugs in the foetal eye. Nature. 1970;227(5264):1257–1258.
   PubMed Web of Science ®Google Scholar
• Hart CW, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol. 1964;80:407–412.
   PubMed Web of Science ®Google Scholar
• Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6):401–404.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003;48(11):3207–3211.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640–3647.
   PubMed Web of Science ®Google Scholar
• Levy M, Buskila D, Gladman DD, et al. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol. 1991;8(3):174–178.
   PubMed Web of Science ®Google Scholar
• Borba EF, Turrini-Filho JR, Kuruma KA, et al. Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. Lupus. 2004;13(4):223–227.
   PubMed Web of Science ®Google Scholar
• Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet. 2001;358(9284):813–814.
   PubMed Web of Science ®Google Scholar
• McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med. 1983;75(1A):11–18.
   PubMed Web of Science ®Google Scholar
• O’Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334(20):1287–1291.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33(9):1053–1058.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013;11(3):318–321.
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4(10):1255–1258.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286–292; quiz e24.
   PubMed Web of Science ®Google Scholar
• Forger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine. 2016;83(3):341–343.
   Google Scholar
• Murashima A, Watanabe N, Ozawa N, et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis. 2009;68(11):1793–1794.
   PubMed Web of Science ®Google Scholar
• Narula N, Al-Dabbagh R, Dhillon A, et al. Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(10):1862–1869.
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Abdolghaffari AH, Nikfar S, et al. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol. 2015;34(5):445–459.
   PubMed Web of Science ®Google Scholar
• Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol. 2012;94(8):607–611.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80(4):727–739.
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, et al. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicology. 2014;43:78–84.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Loftus EV Jr., Jess T. Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11:174.
   PubMed Web of Science ®Google Scholar
• de Lima A, Zelinkova Z, van der Ent C, et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2015 May 12. pii: gutjnl-2015-309321. [Epub ahead of print]
   Google Scholar
• Cheent K, Nolan J, Shariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4(5):603–605.
   PubMed Web of Science ®Google Scholar
• Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis. 2014;20(3):495–501.
   PubMed Web of Science ®Google Scholar